A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1307-1313

  Arkenau, H T ^a,d,e   Plummer, R ^b   Molife, L R ^a   Olmos, D ^a   Yap, T A ^a   Squires, M ^c   Lewis, S ^c   Lock, V ^c   Yule, M ^c   Lyons, J ^c   Calvert, H ^b   Judson, I ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Northern Centre for Cancer Treatment   (United Kingdom)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

^d Sarah Cannon Research UK   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Advanced solid malignancies; AT9283; Aurora kinase inhibitor; Phase I

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; KI 67 ANTIGEN; M30; M56; PHOSPHORYLATION OF HISTONE H3 ON SERINE 10; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SEPSIS; SINGLE DRUG DOSE; VOMITING;

EID: 84860485132     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr451     Document Type: Article

References (27)

1. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4 (11): 842-854.
2. Crane R, Gadea B, Littlepage L et al. Aurora A, meiosis and mitosis. Biol Cell 2004; 96: 215-229.
3. Littlepage LE, Wu H, Andresson T et al. Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A. Proc Natl Acad Sci U S A 2002; 99 (24): 15440-15445.
4. Dutertre S, Cazales M, Quaranta M et al. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. J Cell Sci 2004; 117: 2523-2531.
5. Katayama H, Sasai K, Kawai H et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004; 36: 55-62.
6. Pohl A, Azuma M, Zhang W et al. Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer. Pharmacogenomics J 2011; 11 (2): 93-99.
7. Ditchfield C, Johnson VL, Tighe A et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2 and Cenp-E to kinetochores. J Cell Biol 2003; 161: 267-280.
8. Yasen M, Mizushima H, Mogushi K et al. Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue. Cancer Sci 2009; 100 (3): 472-480.
9. Carpinelli P, Moll J. Aurora kinases and their inhibitors: more than one target and one drug. Adv Exp Med Biol 2008; 610: 54-73.
10. Harrington EA, Bebbington D, Moore J et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumour growth in vivo. Nat Med 2004; 10 (3): 262-267.
11. Howard S, Berdini V, Boulstridge JA et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009; 52 (2): 379-388.
12. Dawson MA, Curry JE, Barber K et al. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. Br J Haematol 2010; 150 (1): 46-57.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 (3): 205-216.
14. Curry J, Angove H, Fazal L et al. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle 2009; 8 (12): 1921-1929.
15. Mahadevan D, Plummer R, Squires MS et al. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann Oncol 2011; 22 (9): 2137-2143.
16. Steeghs N, Eskens FA, Gelderblom H et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009; 27 (30): 5094-5101.
17. Cohen RB, Jones SF, Aggarwal C et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009; 15 (21): 6694-6701.
18. Traynor AM, Hewitt M, Liu G et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 2010 April 13 [epub ahead of print].
19. Rubin EH, Shapiro GI, Stein MN et al. A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. J Clin Oncol 2006; 2006 ASCO Annual Meeting Proceedings Part I. 24 (18 Suppl): 3009.
20. Dees EC, Infante JR, Cohen RB et al. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 67(4): 945-954.
21. Macarulla T, Cervantes A, Elez E et al. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 2010; 9 (10): 2844-2852.
22. Matulonis U, Sharma SK, Ghamande S et al. Single-agent activity and safety of the investigational aurora A kinase inhibitor MLN8237 in patients with platinumtreated epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Ann Oncol 2010; 21 (8): viii305 (Abstr 974).
23. Mross KB, Scheulen ME, Frost A et al. A phase I dose-escalation study of BI811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors. J Clin Oncol 2010; 28: 15s (Abstr 3011).
24. Scharer CD, Laycock N, Osunkoya AO et al. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med 2008; 6: 79.
25. Mazumdar A, Henderson YC, El-Naggar AK et al. Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 2009; 31 (5): 625-634.
26. Gautschi O, Heighway J, Mack PC et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008; 14 (6): 1639-1648.
27. Taga M, Hirooka E, Ouchi T. Essential roles of mTOR/Akt pathway in Aurora-A cell transformation. Int J Biol Sci 2009; 5 (5): 444-450.